Markets & Stocks

Stock quotes, market indicators and the latest market news.

Market Summary Market News Stock Quotes Market Movers
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Maravai LifeSciences Holdings, Inc. - Class A common stock (NQ:MRVI)

7.060 -0.660 (-8.55%)
Delayed Quote Updated: 3:16 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Maravai LifeSciences Holdings, Inc. - Class A common stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Maravai LifeSciences (MRVI) Q3 2026 Earnings Call Transcript ↗
mRNA demand drove growth, and management raised full-year guidance. 
Via The Motley Fool
Topics Earnings
News headline image
What Maravai LifeSciences (MRVI) Said on Its Q3 Earnings Call ↗
Maravai LifeSciences (NASDAQ:MRVI) raised its 2026 revenue and adjusted EBITDA forecasts after reporting third-quarter sales growth of 10%, driven by demand for mRNA products and continued growth at... 
Via MarketBeat
Topics Earnings
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Maravai Lifesciences (NASDAQ:MRVI) Shares Slide Despite Q2 Beat as Full-Year Revenue Outlook Weighs ↗
Via Chartmill
Maravai LifeSciences (NASDAQ:MRVI) Surges After Crushing Q1 Estimates and Raising Full-Year Guidance ↗
Via Chartmill
Maravai Lifesciences (NASDAQ:MRVI) Returns to Positive Adjusted EBITDA and Issues 2026 Guidance ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Maravai LifeSciences's Earnings ↗
 
Via Benzinga
News headline image
Maravai (MRVI) Q2 2026 Earnings Call Transcript ↗
Revenue grew 8.5% to $51.4 million as mRNA discovery demand surged. 
Via The Motley Fool
Topics Earnings
News headline image
Maravai LifeSciences Q2 Earnings Call Highlights ↗
Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its... 
Via MarketBeat
Topics Earnings
News headline image
Maravai (MRVI) Q1 2026 Earnings Transcript ↗
Maravai (MRVI) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Insights Ahead: Maravai LifeSciences's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
Maravai LifeSciences Q1 Earnings Call Highlights ↗
Maravai LifeSciences (NASDAQ:MRVI) reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from... 
Via MarketBeat
Topics Earnings
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
Top movers in Wednesday's after hours session ↗
Via Chartmill
News headline image
Teleflex Stock Slides 39% in a Year, but This $8.5 Million Buy Signals a Contrarian Bet ↗
This medical device firm supplies hospitals worldwide with single-use products for critical care, surgery, and interventional procedures. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About a New $9 Million Bet on an Energy Distributor Stock ↗
This energy sector distributor delivers maintenance, repair, and supply chain solutions to industrial clients across a global network. 
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
This Biopharma Stock Has Surged Nearly 100% and One Fund Just Locked in Gains With a $10 Million Exit ↗
Arcutis Biotherapeutics develops topical therapies for chronic skin conditions, with a portfolio targeting psoriasis and atopic dermatitis. 
Via The Motley Fool
News headline image
Maravai LifeSciences (MRVI) Stock Plummets After Q3 2025 Revenue Miss and Weak Guidance ↗
Maravai LifeSciences (MRVI) stock fell after Q3 2025 revenue missed estimates. The company reported a net loss and provided full-year guidance below analyst expectations. 
Via Chartmill
News headline image
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings.... 
Via MarketMinute
Topics Economy Stocks
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results ↗
 
Via Benzinga
News headline image
Assessing Maravai LifeSciences: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
Breaking Down Maravai LifeSciences: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Trump Media & Technology Group, BitFuFu, Mobileye Global And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
Topics Government
News headline image
Maravai LifeSciences (MRVI) Q4 2024 Earnings Call Transcript ↗
MRVI earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
3 Struggling Stocks Down More Than 50% This Year That Look Cheap But Come With Plenty of Risk ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.